Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial-Reference-Cited by-同舟云学术

Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial

Published:2021-11 Issue:11 Volume:9 Page:743-754
ISSN:2213-8587
Container-title:The Lancet Diabetes & Endocrinology
language:en
Short-container-title:The Lancet Diabetes & Endocrinology

Author:

Heerspink Hiddo J L,Jongs Niels,Chertow Glenn M,Langkilde Anna Maria,McMurray John J V,Correa-Rotter Ricardo,Rossing Peter,Sjöström C David,Stefansson Bergur V,Toto Robert D,Wheeler David C,Greene Tom

Funder

AstraZeneca

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference22 articles.

1. Dapagliflozin in patients with chronic kidney disease;Heerspink;N Engl J Med,2020

2. GFR slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials;Inker;J Am Soc Nephrol,2019

3. Performance of GFR slope as a surrogate end point for kidney disease progression in clinical trials: a statistical simulation;Greene;J Am Soc Nephrol,2019

4. Surrogate end points for clinical trials of kidney disease progression;Stevens;Clin J Am Soc Nephrol,2006

5. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications;Heerspink;Circulation,2016

Cited by 118 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of heart failure and chronic kidney disease protection by SGLT2 inhibitors in nondiabetic conditions;American Journal of Physiology-Cell Physiology;2024-09-01

2. Early Identification and Management of Chronic Kidney Disease: A Narrative Review of the Crucial Role of Primary Care Practitioners;Advances in Therapy;2024-08-20

3. The Impact of Acute Kidney Injury on Chronic Kidney Disease After Cardiac Surgery: A Systematic Review and Meta-analysis;Journal of Cardiothoracic and Vascular Anesthesia;2024-08

4. SGLT2 Inhibitor Use in Chronic Kidney Disease: Supporting Cardiovascular, Kidney, and Metabolic Health;Kidney Medicine;2024-08

5. A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope;Kidney International;2024-08